The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

SINGAPORE – Ketamine, the controlled drug best known ... first authorized sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy on their patients ...

Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about ...

Moreover, at one and two weeks post-infusion, ketamine failed to beat either the saline or the active placebos. Why was the FDA approval of esketamine so controversial among many researchers?

Once sidelined in the 1970s, psychedelic substances—ranging from esketamine (a ketamine derivative) and psilocybin (the active ingredient in hallucinogenic mushrooms) to MDMA—are being ...

Some have already tried numerous medications, as well as ketamine, esketamine, or transcranial magnetic stimulation (TMS). The 2017 National Comorbidity Survey reported that adults with ADHD are ...